Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3221-3233

  Wu, Yan ^a   Sadatmousavi, Parisa ^b   Wang, Rong ^a   Lu, Sheng ^b   Yuan, Yong fang ^a   Chen, P ^b  

^a School of Medicine   (China)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Antitumor; Drug delivery; EAK16 II; Ellipticine; Nanoparticles; Self assembling peptide

Indexed keywords

EAK16 II PEPTIDE; ELLIPTICINE; NANOCARRIER; NANOMATERIAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL SURVIVAL; CELL TRANSPORT; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MALE; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; TUMOR VOLUME;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; ELLIPTICINES; HUMANS; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MICE; MICE, NUDE; NANOCAPSULES; OLIGOPEPTIDES; PARTICLE SIZE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 84870343093     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S31858     Document Type: Article

References (31)

1. Li Q, Tainsky MA. Epigenetic silencing of IRF7 and/or IRF5in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One. 2011;6:e28683.
2. Zhang W, Chen Y, Wei H, etal. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res. 2008;14:6432-6439.
3. Daraselia N, Wang Y, Budoff A, etal. Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am J Cancer Res. 2012;2:93-103.
4. Gong HC, Wang S, Mayer G, etal. Signatures of drug sensitivity in nonsmall cell lung cancer. Int J Proteomics. August 7, 2011. [Epub ahead of print.]
5. Drobnienė M, Cicėnienė A, Zelvienė TP, etal. Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy. Medicina (Kaunas). 2011;47:520-525.
6. Bykadi G, Flora KP, Cradock JC, Poochikian GK. Determination of ellipticine in biological samples by high-performance liquid chromatography. J Chromatogr. 1982;231:137-144.
7. Auclair C. Multimodal action of antitumor agents on DNA: the ellipticine series. Arch Biochem Biophys. 1987;259:1-14.
8. Stiborová M, Bieler CA, Wiessler M, Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol. 2001;62:1675-1684.
9. Singh MP, Hill GC, Péoc'h D, Rayner B, Imbach JL, Lown JW. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry. 1994;33:10271-10285.
10. Monnot M, Mauffret O, Simon V, etal. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem. 1991;266:1820-1829.
11. Fossé P, René B, Charra M, Paoletti C, Saucier JM. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. Mol Pharmacol. 1992;42:590-595.
12. Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem. 1995;270:14998-15004.
13. Stiborová M, Arlt VM, Henderson CJ, etal. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH: cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol. 2008;226:258-327.
14. Poljaková J, Dračínský M, Frei E, Hudeček J, Stiborová M. The effect of PH on peroxidase-mediated oxidation of and DNA adduct formation by ellipticine. Collect Czechoslov Chem Commun. 2009;71:1169-1185.
15. Garbett NC, Graves DE. Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents. 2004;4:149-172.
16. Clarysse A, Brugarolas A, Siegenthaler P, etal. Phase II study of 9-hydroxy-2N-methylellipticinium acetate. Eur J Cancer Clin Oncol. 1984;20:243-247.
17. Wang Y, Li Y, Wang Q, Wu J, Fang X. Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105/L101mixed polymeric micelles. Yakugaku Zasshi. 2008;128:941-950.
18. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem. 2006;384:620-630.
19. Green MR, Manikhas GM, Orlov S, etal. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17: 1263-1268.
20. Corbin IR, Zheng G. Mimicking nature's nanocarrier: synthetic low-density lipoprotein-like nanoparticles for cancer-drug delivery. Nanomedicine (Lond). 2007;2:375-380.
21. Fung SY, Yang H, Chen P. Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticine. PLoS One. 2008;3(4):e1956.
22. Law M, Jafari M, Chen P. Physicochemical characterization of siRNA-peptide complexes. Biotechnol Prog. 2008;24:957-963.
23. Kim SW, Kim NY, Choi YB, Park SH, Yang JM, Shin S. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release. 2010;143:335-343.
24. Zhang S, Holmes T, Lockshin C, Rich A. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc Natl Acad Sci U S A. 1993;90:3334-3338.
25. Fung SY, Oyaizu T, Yang H, etal. The potential of nanoscale combinations of self-assembling peptides and amino acids of the src tyrosine kinase inhibitor in acute lung injury therapy. Biomaterials. 2011;32: 4000-4008.
26. Zhang S, Holmes TC, DiPersio CM, Hynes RO, Su X, Rich A. Self-complementary oligopeptide matrices support mammalian cell attachment. Biomaterials. 1995;16:1385-1393.
27. Fung SY, Yang H, Bhola PT, etal. Self-assembling peptide as a potential as a potential carrier for hydrophobic anticancer drug ellipticine: complexation, release and in vitro delivery. Adv Funct Mater. 2009;19:74-83.
28. Bawa R, Fung SY, Shiozaki A, etal. Self-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis. Nanomedicine. September 1, 2011. [Epub ahead of print.]
29. Zhang S. Emerging biological materials through molecular self-assembly. Biotechnol Adv. 2002;20:321-339.
30. Garbett NC, Graves DE. Extending nature's leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents. 2004;4:149-172.
31. Saijo N, Tamura T, Nishio K. Strategy for the development of novel anticancer drugs. Cancer Chemother Pharmacol. 2003;52 Suppl 1:S97-S101.